Abstract
L1210 and P388 leukemias were developed in 1948 (1) and 1955 (2), respectively. Each leukemia played an important role in both screening and detailed evaluations of candidate anticancer agents. Fifty years later, these in vivo models are still used to evaluate anticancer activity, although at a greatly reduced level. This chapter reviews their past and present role in the evaluation of anticancer drugs. Data on the sensitivity to clinically useful drugs of these two leukemias and the drug-resistant P388 sublines are reported.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
